Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 986-994

  Luo, Weiming ^a   Yu, Qian Sheng ^a   Zhan, Ming ^b   Parrish, Damon ^c   Deschamps, Jeffrey R ^c   Kulkarni, Santosh S ^d   Holloway, Harold W ^a   Alley, George M ^e   Lahiri, Debomoy K ^e   Brossi, Arnold ^f   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c NAVAL RESEARCH LABORATORY   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3A,8 TRIMETHYL 1,2,3,3A,8,8A HEXAHYDROPYRROLO[2,3 B]INDOL 5 YL N ETHYLCARBAMATE; 3A METHYL 2,3,3A,8A TETRAHYDROFURO[2,3 B]BENZOFURAN 5 YL N (2' METHYLPHENYL)CARBAMATE; 3A METHYL 2,3,3A,8A TETRAHYDROFURO[2,3 B]BENZOFURAN 5 YL N ETHYLCARBAMATE; 3A,8 DIMETHYL 2,3,3A,8A TETRAHYDROFURO[2,3 B]INDOL 5 YL N ETHYLCARBAMATE; 4,5 DIHYDRO 2,5 METHANO 5 METHYL 1,3 BENZODIOXEPIN 7 YL N (2' METHYLPHENYL)CARBAMATE; 4,5 DIHYDRO 2,5 METHANO 5 METHYL 1,3 BENZODIOXEPIN 7 YL N ETHYLCARBAMATE; 5 HYDROXY 3 METHYL 3 METHOXYCARBONYLMETHYLENEBENZOFURAN 2(3H) ONE; 5 HYDROXY 3A METHYL 2,3,3A,8A TETRAHYDROFURO[2,3 B]BENZOFURAN; 7 HYDROXY 4,5 DIHYDRO 2,5 METHANO 1,3 BENZODIOXEPINE; ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; BENZOFURAN DERIVATIVE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FUROBENZOFURAN; GALANTAMINE; GANSTIGMINE; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; ISOCYANIC ACID DERIVATIVE; METHANOBENZODIOXEPINE; PHENOL DERIVATIVE; PHENSERINE; PHYSOSTIGMINE DERIVATIVE; PHYSOVENINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYCLIZATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; REDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; AMYLOID BETA-PROTEIN PRECURSOR; BENZOFURANS; BUTYRYLCHOLINESTERASE; CARBAMATES; CELL LINE; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEURONS; OXEPINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13944250571     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049309+     Document Type: Article

References (48)

1. (a) Marion, L. Alkaloids 1952, 2, 438.
2. (b) Coxworth, E. Alkaloids 1965, 8, 27.
3. (c) Robinson, B. Alkaloids 1967, 10, 383.
4. (d) Robinson, B. Alkaloids 1971, 13, 213.
5. (e) Takano, S.; Ogasawara, K. Alkaloids 1989, 36, 889.
6. Dale, F. J.; Robinson, B. The synthesis and anti-acetylcholinesterase activities of (+)-physostigmine and (+)-physovenine. J. Pharm. Pharmacol. 1970, 22, 889-896.
7. Yu, Q. S.; Liu, C.; Brzostowska, M.; Chrisey, L.; Brossi, A.; Greig, N. H.; et al. Physovenines: Efficient Synthesis of (-)- and (+)-Physovenine and Synthesis of Carbamate Analogues of (-)- Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines. Helv. Chim. Acta 1991, 74, 761-766.
8. Lahiri, D. K.; Farlow, M. R.; Sambamurti, K.; Greig, N. H.; Giacobini, E.; Schneider, L. S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 2003, 4, 97-112.
9. Kaplan, D.; Barak, D.; Ordentlich, A.; Kronman, C.; Velan, B.; Shafferman, A. Is aromaticity essential for trapping the catalytic histidine 447 in human acetylcholinesterase? Biochemistry 2004, 43, 3129-36.
10. Soreq, H.; Zakut, H. Human Cholinesterases and Anticholinesterases; Academic Press: New York, 1993.
11. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic Structure of Acetylcholineesterase from Torpedo californica: A Prototypic Acetylcholine-Binding Protein. Science 1991, 253, 872-879.
12. Data were calculated by using software Pallas 3.0 produced by CompuDrug International Inc., 705 Grandniew Drive, South San Francisco, CA 94708.
13. He, X. S.; Greig, N. H.; Broosi, A. Thiaphysovenine and carbamate analogues: a new class of potent inhibitors of cholinesterase. A. Med. Chem. Res. 1992, 2, 229-237.
14. 1. J. Am. Chem. Soc. 1971, 93, 746-752.
15. 2. J. Org. Chem. 1994, 59, 3775-3782.
16. Graybill, T. L.; Casillas, E. G.; Pal, K.; Townsend, C. A. Silyl Triflate-Mediated Ring-Closure and Rearrangement in the Synthesis of Potential Bisfuran-Containing Intermediates of Aflatoxin Biosynthesis. J. Am.Chem. Soc. 1999, 121, 7729-7746.
17. Ozaki, Y.; Quan, Z. S.; Watabe, K. (née Okamura); Kim, S. W. Synthesis of 5-hydroxyoxaindan-2-ones and indol-5-ols from 1,4-cyclohexanedione. Heterocycles 1999, 51, 727-731.
18. Harley-Mason, J.; Jackson, A. H. Hydroxytryptamine. Part II. A New Synthesis of Physostigmine. J. Chem. Soc. 1954, 3651-3654.
19. Shaw, K. T. Y.; Rogers, J.; Utsuki, T.; Yu, Q. S.; Sambamurti, K.; Brossi, A.; Ge, Y. W.; Lahiri, D. K.; Greig, N. H. Phenserine regulates traslation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element: a novel target for drug development. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7605-7610.
20. Sambamurti, K.; Greig, N. H.; Lahiri, D. K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. NeuroMol. Med. 2002, 1, 1-31.
21. Pei, X. F.; Bi, S.; Brossi, A. Reduction of oxindoles with sodium bis(2-methoxyethoxy) aluminum hydride, a novel reducing agent. Heterocycles 1994, 39, 357-360.
22. Brzostowska, M.; He, X. S.; Greig, N. H.; Rapoport, S.; Brossi, A. Phenylcarbamates of (-)-Eceroline and (-)-Physovenol: Selective Inhibition of Acetyl and/or Butyrylcholinesterases by Phenylcarbamates. Med. Chem. Res. 1992, 2, 238-246.
23. Yu, Q. S.; Atack, J. A.; Rapoport, S.; Brossi, A. Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase. FEBS Lett. 1988, 234, 127-130.
24. Atack, J. R.; Yu, Q. S.; Soncrant, T. T.; Brossi, A.; Rapoport, S. Comparative Inhibitory Effects if Variou Physostigmine Analogs against Acetyl- and Butyrylcholinesterases. J. Pharmacol. Exp. Ther. 1989, 249, 194-249.
25. Pei, X. F.; Greig, N. N.; Bi, S.; Broosi, A.; Toome, V. Inhibition of human acetylcholinesterase by unnatural (+)-(3aR)-N1-norphysostigmine and arylcarbamate analogues. Med. Chem. Res. 1995, 5, 265-270.
26. Greig, N. H.; DeMicheli, E.; Utsuki, T.; Holloway, H. W.; Yu, Q. S.; Perry, T. A.; Brossi, A.; Deutsch, J.; Ingram, D. K.; Lahiri, D. K.; Soncrant, T. The experimental Alzheimer drug phenserine: pharmacodynamics and kinetics in the rat. Acta Neurol. Scand. 2000, 102, 74-84.
27. Yu, Q. S.; Holloway, H. W.; Flippen-Anderson, J. L.; Hoffman, B.; Brossi, A.; Greig, N. H. Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationship for acetyl- and butyrylcholinesterase inhibitory action. J. Med. Chem. 2001, 44, 4062-4071.
28. Giacobini, E. Cholinesterase and Cholinesterase Inhibitors; Martin Dunitz: London, 2000.
29. Giacobini, E. Butyrylcholinesterase, Its Function and Inhibitors; Martin Dunitz: London, 2003.
30. 1-norphenserine and its enatiomers: unpredicted inhibition of human acetyl- and butylylcholinesterase and β-amyloid precursor protein in vitro. Heterocydes 2003, 619, 529-539.
31. Nolte, H. J.; Rosenberry, T. L.; Neumann, E. Effective Charge on Acetylcholinesterase Active Sites Determined from the Ionic Strength Dependence of Association Rate Constants with Cationic Ligands. Biochemistry 1980, 19, 3705-3711.
32. Ripoll, D. R.; Faerman, C. H.; Axelsen, P. H.; Silman, I.; Sussman, J. L. An Electrostatic Mechanism for Substrate Guidance down the Aromatic Gorge of Acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5128-5132.
33. Tan, R. C.; Truong, T. N.; McCammon, J. A.; Sussman, J. L. Acetylcholinesterase: Electrostatic Steering Increases the Rate of Ligand Binding. Biochemistry 1993, 32, 401-403.
34. Bartolucci, C.; Perola, E.; Cellai, L.; Brufani, M.; Lamba, D. "Back Door" Opening Implied by the Crystal Structure of Carbamoylated Acetylcholinesterase. Biochemistry 1999, 38, 5714-5719.
35. Gilson, M. K.; Straatsma, J. A.; McCammon, J. A.; Ripoll, D. R.; Faerman, C. H.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Open "Back Door" in a Molecular Dynamics Simulation of Acetylcholinesterase. Science 1994, 263, 1276-1278.
36. Koellner, G.; Steiner, T.; Millard, C. B.; Silman, I.; Sussman, J. L. A Neutral Molecule in a Cation-Binding Site: Specific Binding of a PEG-SH to Acetylcholinesterase from Torpedo californica. J. Mol. Biol. 2002, 320, 721-725.
37. Pei, X. F.; Yu, Q. S.; Holloway, H. W.; Brossi, A.; Greig, N. H. Syntheses and biological evaluation of ring-C opened analogues of the Cholinesterase inhibitors physostigmine, phenserine and cymserine. Med. Chem. Res. 1999, 9, 50-60.
38. Lahiri, D. K.; Alley, M.; Farlow, H.; Rogers, J. T.; Greig, N. H. Physostigmine and its analogue phenserine have different effects of Alzheimer's amyloid-beta precursor protein. In Progress in Alzheimer's and Parkinson's Disease; Hanin, I., Fisher, A., Eds., in press.
39. Maloney, B.; Ge, Y.; Greig, N. H.; Lahiri, D. K. Characterization of the 5′-untranslated region of APP mRNA: implications in drug development for Alzheimer's disease. FASEB J. 2004, 18, 1288-1290.
40. Computer software used for X-ray crystallography: (a) SMART, version 5.625; Bruker AXS Inc.: Madison, WI, 2001.
41. (b) SAINT, version 6.36A; Bruker AXS Inc.: Madison, WI, 2002.
42. (c) XPREP, version 6.12; Bruker AXS Inc.: Madison, WI, 2001.
43. (d) TWIN-ABS, version 1.05; Bruker AXS Inc.: Madison, WI, 2003.
44. (e) SHELXTL, version 6.10; Bruker AXS Inc.; Madison, WI, 2000.
45. Lahiri, D. K.; Farlow, M. R.; Sambamurti, K. The Secretion of Amyloid-beta Peptides Is Inhibited in Tacrine-Treated Human Neuroblastoma Cells. Mol. Brain Res. 1998, 62, 131-140.
46. Zhu, X.; Yu, Q. S.; Cutler, R. G.; Culmsee, C.; Holloway, H. W.; Mattson, M. P.; Greig, N. H. Novel p53 inhibitors with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J. Med. Chem. 2002, 45, 5090-5097.
47. Yamamoto, Y.; Ishihara, Y.; Kuntz, I. D. Docking Analysis of a Series of Benzylamino Acetylcholinesterase Inhibitors with a Phthalimide, Benzoyl, or Indanone Moiety. J. Med. Chem. 1994, 37, 3141-3153.
48. Enz, A.; Amstutz, R.; Boddeke, H.; Gmelin, G.; Malanowski, J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy in Alzheimer's disease. Prog. Brain Res. 1993, 98, 431-438.